CLYM

Climb Bio
CLYM

Overview Fund Trends Analyst Outlook Journalist POV
2.26 USD
--0.06
2.59%
At close Updated Oct 21, 4:00 PM EDT
Pre-market
After hours
2.16
--0.10
4.42%
1 day
-2.59%
5 days
18.95%
1 month
-2.59%
3 months
60.28%
6 months
83.74%
Year to date
9.18%
1 year
-52.92%
5 years
-85.79%
10 years
-85.79%
 

About: Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.

Employees: 18

Healthcare Biotechnology
0
Funds holding %
of 7,499 funds
Explore Fund Trends
0
Analysts bullish %
of 3 analysts
See Analyst Outlook
0
Positive news %
of 4 articles
Check Journalist POV
Price charts implemented using Lightweight Charts™